Influence of the novel antidepressant and melatonin agonist/serotonin2C receptor antagonist, agomelatine, on the rat sleep–wake cycle architecture

Rationale The novel antidepressant, agomelatine, behaves as an agonist at melatonin MT1 and MT2 receptors and as an antagonist at serotonin (5-HT)2C receptors. In animal models and clinical trials, agomelatine displays antidepressant properties and re-synchronizes disrupted circadian rhythms.